KDR and hereditary clear cell renal cell carcinoma: However, unlike sorafenib, UC2288 has minimal inhibitory properties on vascular endothelial growth factor receptor 2 (VEGFR2) and Raf kinase activity as evidenced by the finding that changes of p-ERK levels varied in renal cell carcinoma cell lines and a normal kidney cell treated with UC2288 4.